NanoRepro AG Asset Resilience Ratio
NanoRepro AG asset resilience ratio. NanoRepro AG (NN6) has an Asset Resilience Ratio of 19.19% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of NanoRepro AG to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NanoRepro AG (2010–2024)
Asset resilience ratio of NanoRepro AG from 2010 to 2024. This chart shows how NanoRepro AG's Asset Resilience Ratio has changed over time. Read debt load of NanoRepro AG for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down NanoRepro AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NanoRepro AG total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €7.29 Million | 19.19% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €7.29 Million | 19.19% |
Asset Resilience Insights
- Good Liquidity Position: NanoRepro AG maintains a healthy 19.19% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
NanoRepro AG Industry Peers by Asset Resilience Ratio
Compare NanoRepro AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Lonza Group AG
SW:LONN |
Diagnostics & Research | 3.04% |
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB |
Diagnostics & Research | 13.43% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
NanoRepro AG Asset Resilience Ratio by Year (2010–2024)
NanoRepro AG asset resilience ratio by year from 2010 to 2024. The table below shows the annual Asset Resilience Ratio data for NanoRepro AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 23.31% | €9.10 Million ≈ $10.64 Million |
€39.03 Million ≈ $45.62 Million |
-26.43pp |
| 2023-12-31 | 49.74% | €20.62 Million ≈ $24.11 Million |
€41.46 Million ≈ $48.47 Million |
-13.44pp |
| 2022-12-31 | 63.18% | €31.26 Million ≈ $36.55 Million |
€49.48 Million ≈ $57.84 Million |
+27.78pp |
| 2021-12-31 | 35.40% | €28.02 Million ≈ $32.76 Million |
€79.15 Million ≈ $92.53 Million |
+24.98pp |
| 2020-12-31 | 10.42% | €1.16 Million ≈ $1.36 Million |
€11.17 Million ≈ $13.06 Million |
-4.93pp |
| 2019-12-31 | 15.35% | €737.15K ≈ $861.81K |
€4.80 Million ≈ $5.62 Million |
-15.13pp |
| 2018-12-31 | 30.48% | €1.77 Million ≈ $2.07 Million |
€5.81 Million ≈ $6.79 Million |
+17.90pp |
| 2017-12-31 | 12.58% | €528.05K ≈ $617.35K |
€4.20 Million ≈ $4.91 Million |
-2.51pp |
| 2016-12-31 | 15.09% | €530.12K ≈ $619.77K |
€3.51 Million ≈ $4.11 Million |
+14.98pp |
| 2010-12-31 | 0.11% | €2.15K ≈ $2.52K |
€1.94 Million ≈ $2.27 Million |
-- |
About NanoRepro AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preve… Read more